
Yuki Takamatsu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1421374/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Journal of Virology, 2022, 96, JVI0155121.	3.4	18
2	Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. GHM Open, 2022, 2, 38-43.	0.6	4
3	Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. Journal of Infection and Chemotherapy, 2022, 28, 991-994.	1.7	4
4	A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy. International Journal of Infectious Diseases, 2022, 121, 85-88.	3.3	4
5	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). Life, 2022, 12, 856.	2.4	4
6	A small moleculeÂcompound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications, 2021, 12, 668.	12.8	126
7	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Scientific Reports, 2021, 11, 5563.	3.3	42
8	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Scientific Reports, 2021, 11, 22848.	3.3	57
9	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. MBio, 2020, 11, .	4.1	52
10	A familial cluster of severe coronavirus disease 2019 that required intubation of all family members. Infectious Diseases, 2020, 52, 755-758.	2.8	0
11	Potent HIVâ€l Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Proteinâ€Ligand Xâ€ray Structural Studies. ChemMedChem, 2019, 14, 1863-1872.	3.2	16
12	Novel Protease Inhibitors Containing C-5-Modified <i>bis</i> -Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
13	A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. Global Health & Medicine, 2019, 1, 36-48.	1.4	5
14	GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	8
15	Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. MBio, 2018, 9, .	4.1	36
16	Synthesis of 4′â€5ubstituted Purine 2′â€Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. ChemistrySelect, 2018, 3, 3313-3317.	1.5	6
17	The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. Cell Chemical Biology, 2018, 25, 1268-1278.e3.	5.2	20
18	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. ELife, 2017, 6, .	6.0	44

Υυκι Τακαματςυ

#	Article	IF	CITATIONS
19	Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget, 2017, 8, 50342-50358.	1.8	28
20	Novel 4'-modified nucleoside analogs exert antiviral replication against hepatitis B virus with drug resistance mutations. Acta Hepatologica Japonica, 2016, 57, 299-301.	0.1	0
21	C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. Journal of Virology, 2016, 90, 2180-2194.	3.4	15
22	4′â€modified nucleoside analogs: Potent inhibitors active against entecavirâ€resistant hepatitis B virus. Hepatology, 2015, 62, 1024-1036.	7.3	43